title: Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
abstract: The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.
authors.forename: Maria Luigia
authors.initials: ML
authors.lastname: Randi
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Ruzzon
authors.forename: Guido
authors.initials: G
authors.lastname: Luzzatto
authors.forename: Fabiana
authors.initials: F
authors.lastname: Tezza
authors.forename: Antonio
authors.initials: A
authors.lastname: Girolami
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Fabris
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002066:Busulfan / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000494:pharmacology*; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000188:drug therapy; D011087:Polycythemia Vera / Q000188:drug therapy*; D012189:Retrospective Studies; D013922:Thrombocytosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D002066:Busulfan; D006918:Hydroxyurea